- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07640243
Sedation Methods in Percutaneous Transhepatic Biliary Drainage: Procedure Quality and Recovery
Evaluation of Sedation Methods Used in Percutaneous Transhepatic Biliary Drainage Procedures in Terms of Procedure Quality, Recovery Time, and Side Effects
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Percutaneous transhepatic biliary drainage (PTBD) is a therapeutic procedure commonly performed in patients with biliary obstruction when surgical intervention or endoscopic retrograde cholangiopancreatography is not feasible. These patients frequently present with advanced age, malignancy, cholangitis, and significant comorbidities, making them particularly vulnerable to sedation-related complications.
Procedural sedation and analgesia are commonly used during interventional radiology procedures to ensure patient comfort, immobility, and procedural success. However, inadequate sedation may result in patient movement, increased anxiety, procedural failure, and complications, whereas excessive sedation may lead to hemodynamic instability, respiratory depression, and delayed recovery, especially in frail patients.
In this study, two commonly used sedation regimens-propofol combined with remifentanil and propofol combined with ketamine-will be compared. Both regimens are routinely used in non-operating room anesthesia settings in our institution. Patients will be randomly assigned in a 1:1 ratio to one of the two groups. Standard monitoring will be applied, including non-invasive blood pressure, electrocardiography, and pulse oximetry, with supplemental oxygen administered via nasal cannula.
Sedation depth will be targeted to a Ramsay Sedation Score of 3-4 and assessed every five minutes during the procedure. Hemodynamic parameters, oxygen saturation, pain scores, recovery time, and adverse events such as hypotension, bradycardia, hypoxia, nausea, vomiting, and airway interventions will be recorded. Recovery will be evaluated using the Modified Aldrete Score at two-minute intervals until adequate recovery is achieved.
The primary objective of the study is to compare recovery times between the two sedation regimens. Secondary objectives include comparison of pain intensity, patient and operator satisfaction, total drug consumption, procedural tolerance, and incidence of adverse events. The findings of this study aim to contribute to safer and more effective sedation strategies for PTBD procedures in high-risk patient populations.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ankara
-
Ankara, Ankara, Turquía (Türkiye), 06800
- Reclutamiento
- Ankara Bilkent City Hospital
-
Contacto:
- Mücahid MD Mutlu, Resident
- Número de teléfono: +905078260298
- Correo electrónico: mucahid.mutlu@gmail.com
-
Contacto:
- Mücahid Mutlu
- Número de teléfono: +905078260298
- Correo electrónico: mucahid.mutlu@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Scheduled for elective percutaneous transhepatic biliary drainage (PTBD) and/or biliary stenting
- ASA physical status II-IV
- Fasting time of at least 6 hours prior to the procedure
- Ability to provide written informed consent
Exclusion Criteria:
- Inability to provide informed consent or to complete study assessments (e.g., Ramsay Sedation Scale, FRAIL scale, Numeric Rating Scale)
- Clinical diagnosis of Alzheimer's Disease
- Clinical diagnosis of demantia
- Known allergy or hypersensitivity to propofol, remifentanil, ketamine, ondansetron, or deksketoprofen
- Grade 3-4 aortic, mitral, or tricuspid valve disease
- Advanced or decompensated heart failure (ejection fraction <25%)
- Emergency procedures
- Refusal to participate in the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Propofol-Remifentanil
Participants received intravenous propofol 0.5 mg/kg followed by a continuous intravenous remifentanil infusion initiated at 0.10-0.18
mcg/kg/min during the procedure.
The remifentanil infusion rate was adjusted within the specified range according to clinical response to maintain adequate sedation, analgesia, and hemodynamic stability throughout the procedure.
|
Intravenous propofol combined with remifentanil infusion for procedural sedation during percutaneous transhepatic biliary drainage.
|
|
Experimental: Propofol-Ketamine
IParticipants received intravenous propofol 0.5 mg/kg followed by intravenous ketamine 0.3 mg/kg.
Additional intravenous ketamine 5 mg was administered every 5 minutes as needed during the procedure to maintain the target sedation level and hemodynamic stability.
|
Intravenous propofol combined with ketamine bolus for procedural sedation during percutaneous transhepatic biliary drainage.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recovery Time
Periodo de tiempo: From completion of the procedure until Modified Aldrete Score >8, assessed up to 30 minutes
|
Time to achieve adequate recovery assessed using the Modified Aldrete Score.
|
From completion of the procedure until Modified Aldrete Score >8, assessed up to 30 minutes
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Hemodynamic Stability
Periodo de tiempo: Baseline, every 5 minutes during the procedure (assessed up to 60 minutes), and immediately after the procedure.
|
Changes in systolic, diastolic, and mean arterial blood pressure, heart rate, and oxygen saturation during the procedure.
|
Baseline, every 5 minutes during the procedure (assessed up to 60 minutes), and immediately after the procedure.
|
|
Pain Intensity
Periodo de tiempo: Baseline (pre-procedure), immediately after recovery, and at 30 minutes post-recovery.
|
Pain intensity assessed using the Numeric Rating Scale (NRS)
|
Baseline (pre-procedure), immediately after recovery, and at 30 minutes post-recovery.
|
|
Sedation Depth
Periodo de tiempo: Every 5 minutes during the procedure, assessed up to 30 minutes.
|
Sedation level assessed using the Ramsay Sedation Scale.
|
Every 5 minutes during the procedure, assessed up to 30 minutes.
|
|
Adverse Events
Periodo de tiempo: Perioperatively and through the recovery period, assessed up to 30 minutes.
|
Incidence of sedation-related adverse events including hypotension, bradycardia, hypoxia, apnea, nausea, and vomiting.
|
Perioperatively and through the recovery period, assessed up to 30 minutes.
|
|
Patient and Operator Satisfaction
Periodo de tiempo: Immediately after the procedure
|
Patient and operator satisfaction assessed after completion of the procedure.
|
Immediately after the procedure
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Enfermedades del Tracto Biliar
- Enfermedades de las vías biliares
- Neoplasias
- Colangitis
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Hidrocarburos
- Ciclohexanos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Ácidos, acíclico
- Ácidos carboxílicos
- Piperidinas
- Propionios
- Remifentanilo
- Ketamina
Otros números de identificación del estudio
- TABED-1-25-1188
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Remifentanil
-
Nordsjaellands HospitalAún no reclutandoEl dolor del partoDinamarca
-
Sakarya UniversityTerminadoAnestesia general | Monitoreo intraoperatorio | Profundidad anestésicaTurquía (Türkiye)
-
Seoul National University HospitalAún no reclutando
-
University General Hospital of PatrasReclutamientoIsquemia cerebral | Ketamina | Sulfato de magnesio | Remifentanilo | Anestesia con sevoflurano | Propofol/Remifentanilo | S 100beta | Proteína beta S100, humano | Enolasa específica de neuronasGrecia
-
Harbin Medical UniversityFirst Affiliated Hospital of Harbin Medical UniversityReclutamientoEnfermedad gastrointestinalPorcelana
-
Ataturk Training and Research HospitalTerminadoAnestesia | Presión intraocular | Anestesia Intravenosa Total | Anestesia por inhalación | Prostatectomía radical laparoscópica asistida por robot | Posición de Trendelenburg
-
Ankara City Hospital BilkentTerminadoColonización Microbiana | Anestesia general | Anestesia por inhalación | Anestesia de flujo mínimo | Riesgo de infección | Circuito de anestesia | Equipo de anestesia Contaminación bacterianaTurquía (Türkiye)